Literature DB >> 22874113

A rare cause of childhood-onset nephrotic syndrome: lipoprotein glomerulopathy.

Min-Tser Liao1, I-Jung Tsai, Hui-Teng Cheng, Wei-Chou Lin, Yen-Wen Chang, Yi-Heng Lin, Yong-Kwei Tsau.   

Abstract

We report on a 12-year-old female patient with lipoprotein glomerulopathy (LPG) who was proven to be heterozygous for ApoE2 Kyoto (Arg25Cys). Her family members have the same variant but do not have obvious signs of renal function impairment. Six months of treatment with a statin caused significant clinical improvement in the lipid profile, proteinuria, and renal function. Our case suggests that administration of a statin is a potential therapeutic strategy for improving nephrotic syndrome in patients with LPG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22874113     DOI: 10.5414/cn106876

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation.

Authors:  Ryosuke Usui; Masaki Takahashi; Kosaku Nitta; Minako Koike
Journal:  CEN Case Rep       Date:  2016-03-04

Review 2.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 3.  Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.

Authors:  Eduardo Cambruzzi; Karla Lais Pêgas
Journal:  J Bras Nefrol       Date:  2018-11-08

4.  A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.

Authors:  Runxiu Wang; Chengbo Zhao; Wen Chen; Zhiping Liu; Fuhua Xie
Journal:  J Med Case Rep       Date:  2022-02-23

5.  Lipoprotein glomerulopathy resulting from compound heterogeneous mutations of APOE gene: A case report.

Authors:  Yunsi Li; Jin Chen; Yurong Zou; Wei Wang; Guisen Li
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.